March 23, 2023
Owler
Agile Therapeutics's revenue changed from $8.40M in Sep 2022 to $10.88M in Dec 2022
Agile Therapeutics’s Trailing Twelve Months revenue changed from $8.40M in Sep 2022 to $10.88M in Dec... See more »
XBiotech: XBiotech Announces First Patient Enrolled in Phase I Clinical Trial for Novel Arthritis Therapy Natrunix-SQ
(marketscreener.com) Natrunix-SQ, A True Human Antibody Therapy Discovered and Manufactured at XBiotech, Is Aimed as a Breakthrough Treatment for Arthritic DiseaseAUSTIN, Texas, Jan. 26, 2022 -- XBiotech Inc. enrolled the first patient in a randomized, double-blind, placebo-controlled clinical study to evaluate safety and pharmacokinetics of Natrunix-SQ....https://www.marketscreener.com/quote/stock/XBIOTECH-INC-21506504/news/XBiotech-Announces-First-Patient-Enrolled-in-Phase-I-Clinical-Trial-for-Novel-Arthritis-Therapy-Natr-37649055/?utm_medium=RSS&utm_content=20220126
Read full article »
March 24, 2023
Benzinga
Regeneron Pharmaceuticals Options Traders Betting On Stock Falling This Much By April Expiration
Sanofi (NASDAQ: SNY) and Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) shares surged on Thursday aft... See more »
March 23, 2023
Owler
Agile Therapeutics's revenue changed from $8.40M in Sep 2022 to $10.88M in Dec 2022
Agile Therapeutics’s Trailing Twelve Months revenue changed from $8.40M in Sep 2022 to $10.88M in Dec... See more »
March 24, 2023
Benzinga
Regeneron Pharmaceuticals Options Traders Betting On Stock Falling This Much By April Expiration
Sanofi (NASDAQ: SNY) and Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) shares surged on Thursday aft... See more »
XBiotech is a biopharmaceutical company that develops antibody therapies for inflammatory diseases and colorectal cancer.
Read more